All data are based on the daily closing price as of April 1, 2025
e

Ever Supreme Bio Technology

6712.TWO
5.18 USD
0.09
+1.77%

Overview

Last close
5.18 usd
Market cap
379.95M usd
52 week high
6.51 usd
52 week low
5.09 usd
Target price
N/A usd

Valuation

P/E
37.8022
Forward P/E
N/A
Price/Sales
16.2734
Price/Book Value
7.5289
Enterprise Value
378.72M usd
EV/Revenue
13.4648
EV/EBITDA
25.5687

Key financials

Revenue TTM
25.45M usd
Gross Profit TTM
17.82M usd
EBITDA TTM
11.98M usd
Earnings per Share
0.14 usd
Dividend
0.16 usd
Total assets
55.41M usd
Net debt
-7.90M usd

About

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. The company was incorporated in 2016 and is based in Taichung, Taiwan.
  • Symbol
    6712.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
  • Headquarter
    Taichung
  • Web site
    https://www.ever-supreme.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top